Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

May 2020 – Biomarkers & Genetic Testing

Let’s Talk About Biomarkers
This special issue of CONQUER magazine is focused on very innovative diagnostic tests that involve biomarkers associated with cancer. For many past decades we have provided the same types of treatments for patients with cancer, basing the treatments on the type of cancer the patient had, and where it was in the body, such as lung cancer or breast cancer. Read More ›

What Are Biomarkers and Precision Medicine in Oncology? An Interview with W. Michael Korn, MD
Understanding the specific biomarkers associated with each patient’s cancer helps to select the best therapy that targets that unique biomarker to improve the chance of survival for that patient. Read More ›

Genetic, Genomic, or Biomarker Testing in Cancer—What Is the Difference?
Genetic testing, genomic testing, molecular profiling—how can you make sense of these terms to ensure you receive the best test and best treatment in this era of targeted therapies? A group of experts and patient advocates provide answers to these questions. Read More ›

Being a Caregiver for a Patient with Cancer During Quarantine
Shera Dubitsky, MEd, MA, uses her personal experience caring for her father from afar during the COVID-19 pandemic to offer tips on distant caregiving for patients with cancer. Read More ›

Biomarker Testing Crucial for Patients with Cholangiocarcinoma
New treatments are becoming available for patients with cholangiocarcinoma (bile duct cancer). Testing for specific biomarkers is crucial to ensure each patient receives the best available treatment for any associated biomarker. Read More ›

Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion. Read More ›

Role of Biomarkers in Guiding Treatment for Breast Cancer
Breast cancer is the second most common cancer among women, but it is important to remember that men can also have breast cancer. Recent advances in therapy have led to the discovery of specific biologic markers (biomarkers) in cancer cells, which has further led to the development of drugs known as targeted therapies. Read More ›

Tukysa Approved for Breast Cancer and HER2 Biomarker
Another drug approved by the FDA in April, Tukysa, a kinase inhibitor, is a new treatment option for the treatment of patients with advanced HER2-positive breast cancer. Read More ›

Biomarkers in Lung Cancer: What Are They and Why Do They Matter?
Patients with advanced lung cancer should be tested for the 5 most common biomarkers so they may receive the best treatment options for their disease. Read More ›